Transtympanic management of tinnitus.
Transtympanic therapy is becoming and important treatment modality for many inner ear disorders. The current therapies aimed at Meniere's disease, sudden sensorineural hearing loss, noise-induced hearing loss, and the tinnitus associated with these disorders and idiopathic tinnitus, however, represents simply an evolutionary step in this treatment modality and must be validated by further scientific study. A number of promising developments including newer more targeted neuroactive medicines, a better understanding of medicine delivery, and the knowledge of the site, origin, and pathophysiology of the symptoms complex will make this therapy more effective. In the future it is possible that many inner ear disorders will be amenable to inner ear medical therapy. Ideally in the future with knowledge of the disease and its etiology the physician will simply pick the established medicine, the established dose, and the established route of administration and achieve a relatively predictable result.
Hoffer
Michael E
ME
Department of Defense Spatial Orientation Center, Department of Otolaryngology, Naval Medical Center San Diego, San Diego, CA 92134-2200, USA. mehoffer@nmcsd.med.navy.mil
Wester
Derin
D
Kopke
Richard D
RD
Weisskopf
Peter
P
Gottshall
Kim
K
D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D005260:Female; D005839:Gentamicins / Q000008:administration & dosage*; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D007267:Injections; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage*; D014012:Tinnitus / Q000188:drug therapy*; D014432:Tympanic Membrane
D000900:Anti-Bacterial Agents; D003692:Delayed-Action Preparations; D005839:Gentamicins; D005938:Glucocorticoids; D008775:Methylprednisolone